FDA's Premarket Policy For Device Reprocessors Questioned By Congressmen
This article was originally published in The Gray Sheet
Executive Summary
FDA review standards for premarket applications submitted by reprocessors of single-use devices (SUDs) must be clarified to address the issue of one-time reuse versus multiple reuse, House Commerce Committee Chair Thomas Bliley (R-Va.) and Oversight and Investigations Subcommittee Chair Fred Upton (R-Mich.) maintain in a Nov. 1 letter to the agency.
You may also be interested in...
Reuse 510(k)s Should Be Required For Class I Forceps - Boston Scientific
FDA should remove the current exemption from premarket notification requirements for reprocessors of single use non-electric biopsy forceps, Boston Scientific maintains in a citizen petition filed by the agency Sept. 27.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.